Regulatory November date set for FDA decision on Sanofi’s Gaucher drug PharmaphorumThe FDA has started a priority review of Sanofi's brain-acting Gaucher disease therapy venglustat, with an action date of 25th November.Rare DiseaseRead full story pharminent May 28, 2026 (Last updated: May 30, 2026) Pharmaphorum The FDA has started a priority review of Sanofi’s brain-acting Gaucher disease therapy venglustat, with an action date of 25th November. Rare Disease Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Kailera’s three-pronged obesity shot shows promise in early trialNext: AbbVie snags FDA’s first ADC approval for ultra-rare blood cancer Related Stories Regulatory FDA approves MSD’s Keytruda combinations for MIBC pharminent July 13, 2026 Regulatory FDA freezes CRL trove as ‘radical transparency’ push hits speedbump pharminent July 9, 2026 Regulatory UK first in Europe to clear Boehringer’s IPF drug Jascayd pharminent July 9, 2026
